Investment analysts at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of NASDAQ PULM opened at $2.19 on Monday. The stock has a market capitalization of $8.00 million, a PE ratio of -0.91 and a beta of 0.99. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $2.75. The stock has a 50 day moving average price of $2.10 and a 200 day moving average price of $1.98.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. The business had revenue of $1.55 million for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- What is Forex and How Does it Work?
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How to Find Undervalued Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The 3 Best Fintech Stocks to Buy Now
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
